Poteligeo

1 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX I 
 

SUMMARY OF PRODUCT CHARACTERISTICS 



2 

This medicinal product is subject to additional monitoring. This will allow quick identification of 
new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 
See section 4.8 for how to report adverse reactions. 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
POTELIGEO 4 mg/mL concentrate for solution for infusion. 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Each vial contains 20 mg of mogamulizumab in 5 mL, corresponding to 4 mg/mL. 
 
Mogamulizumab is produced in Chinese hamster ovary cells by recombinant DNA technology. 
 
For the full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Concentrate for solution for infusion. 
 
Clear to slightly opalescent, colourless solution. 
 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
 
POTELIGEO is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary 
syndrome (SS) who have received at least one prior systemic therapy. 
 
4.2 Posology and method of administration 
 
Treatment must be initiated and supervised by physicians experienced in the treatment of cancer, and 
should only be administered by healthcare professionals in an environment where resuscitation 
equipment is available.  
 
Posology 
The recommended dose is 1 mg/kg mogamulizumab administered as an intravenous infusion over at 
least 60 minutes. Administration is weekly on days 1, 8, 15 and 22 of the first 28-day cycle, followed 
by infusions every two weeks on Days 1 and 15 of each subsequent 28-day cycle until disease 
progression or unacceptable toxicity.  
 
POTELIGEO should be administered within 2 days of the scheduled day. If a dose is missed by more 
than 2 days, the next dose should be administered as soon as possible, after which the dosing schedule 
should be resumed with doses given based on the new scheduled days. 
 
Pre-medication with anti-pyretic and anti-histamine is recommended for the first POTELIGEO 
infusion. If an infusion reaction occurs, administer pre-medication for subsequent POTELIGEO 
infusions.  
 
Dose modification 
Dermatologic reactions 
Patients receiving mogamulizumab have experienced drug rash (drug eruption), some of which were 
severe and/or serious. 



3 

• In the event of a rash (drug related) with severity of Grade 2 or 3 (moderate or severe), 
treatment with mogamulizumab must be interrupted and the rash should be treated appropriately 
until rash improves to Grade 1 or less (mild severity), at which time mogamulizumab treatment 
may be resumed. 

• POTELIGEO should be permanently discontinued for a life-threatening (Grade 4) rash (see 
section 4.4). 

 
Infusion-related reactions 
• The infusion of POTELIGEO should be temporarily interrupted for mild to severe (Grades 1-3) 

infusion-related reactions and symptoms treated. The infusion rate should be reduced by at least 
50% when re-starting the infusion after symptoms resolve. If reaction recurs, discontinuing the 
infusion should be considered (see section 4.4). 

• POTELIGEO should be permanently discontinued for a life-threatening (Grade 4) 
infusion-related reaction (see section 4.4). 

 
Special populations 
 
Paediatric population 
The safety and efficacy of POTELIGEO in children and adolescents aged below 18 years has not been 
established. No data are available. 
 
Elderly 
No dose adjustment is required in elderly patients (see section 5.2).  
 
Renal impairment 
Based on a population pharmacokinetic analysis, no dose adjustment is recommended in patients with 
mild to severe renal impairment (see section 5.2). 
 
Hepatic impairment 
Based on a population pharmacokinetic analysis, no dose adjustment is recommended in patients with 
mild or moderate hepatic impairment. POTELIGEO has not been studied in patients with severe 
hepatic impairment (see section 5.2). 
 
Method of administration 
POTELIGEO is for intravenous use. It should be administered by intravenous infusion only, over at 
least 60 minutes. See above recommendations in case of infusion-related reaction. 
 
For instructions on the dilution of the medicinal product before administration, see section 6.6. 
 
4.3 Contraindications 
 
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
 
4.4 Special warnings and precautions for use 
 
Dermatologic reactions 
Patients receiving mogamulizumab have experienced drug rash (drug eruption), some of which were 
severe and/or serious.  
 
When mogamulizumab has been administered to patients with T-cell lymphomas other than MF or SS, 
serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis 
(TEN), have been reported in less than 1% of patients during clinical trials, and also reported during 
the post-marketing period; some of these cases were reported with fatal outcomes. Patients should be 
closely monitored for symptoms or signs that suggest SJS or TEN. If they occur, POTELIGEO should 
be interrupted and treatment should not restart unless SJS or TEN is ruled out and cutaneous reaction 
has resolved to Grade 1 or less. If SJS/TEN occur, appropriate medical therapy should be 
administered. See section 4.2 for dose modification information. 



4 

 
Infusion-related reactions  
Acute infusion-related reactions (IRRs) have been observed in patients treated with mogamulizumab. 
The IRRs were mostly mild or moderate in severity, although there have been a few reports of severe 
reactions (Grade 3). The majority of IRRs occur during or shortly after the first infusion (all within 
24 hours of administration), with the incidence decreasing over subsequent treatments.  
 
Patients should be carefully monitored during and after infusion. If an anaphylactic reaction occurs, 
administration of mogamulizumab should be immediately and permanently discontinued and 
appropriate medical therapy should be administered. 
 
If an IRR occurs, the infusion should be interrupted and appropriate medical management instituted. 
The infusion may be restarted at a slower rate after symptom resolution. See section 4.2 for pre-
medication and dose modification information. 
 
Infections 
Subjects with MF or SS treated with mogamulizumab are at increased risk of serious infection and/or 
viral reactivation. The combination of mogamulizumab with systemic immune modulating medicinal 
products or with other licensed therapies for MF or SS has not been studied and is, therefore, not 
recommended, especially in consideration of the risk of severe infections in patients treated with 
mogamulizumab. Topical steroids or low doses of systemic corticosteroids may be used during 
treatment with mogamulizumab; however, the risk of serious infection and/or viral reactivation may be 
higher in case of concomitant administration with systemic immunosuppressive agents. Patients 
should be monitored for signs and symptoms of infection and treated promptly. 
 
Patients should be tested for hepatitis B infection before initiating treatment with mogamulizumab. For 
patients who test positive for current/previous hepatitis B infection, consultation with a physician with 
expertise in the treatment of hepatitis B is recommended for advice concerning appropriate measures 
against hepatitis B reactivation. 
 
Complications of allogeneic hematopoietic stem cell transplantation (HSCT) after mogamulizumab  
Complications, including severe graft versus host disease (GVHD), have been reported in patients 
with T-cell lymphomas other than MF or SS who received allogeneic HSCT after mogamulizumab.  
 
A higher risk of transplant complications has been reported if mogamulizumab is given within a short 
time frame (approximately 50 days) before HSCT. Follow patients closely for early evidence of 
transplant-related complications. 
 
The safety of treatment with mogamulizumab after autologous or allogeneic HSCT has not been 
studied. 
 
Tumour lysis syndrome  
Tumour lysis syndrome (TLS) has been observed in patients receiving mogamulizumab. TLS was 
observed most frequently during the first month of treatment. Patients with rapidly proliferating 
tumour and high tumour burden are at risk of TLS. Patients should be monitored closely by 
appropriate laboratory and clinical tests for electrolyte status, hydration and renal function, particularly 
in the first month of treatment, and managed according to best medical practice. Management of TLS 
may include aggressive hydration, correction of electrolyte abnormalities, anti-hyperuricaemic 
therapy, and supportive care. 
 
Cardiac disorders 
One case of acute myocardial infarction has been observed in a clinical trial patient with MF / SS 
receiving mogamulizumab. In clinical trial patients with other T-cell lymphomas there have been 
reports of stress cardiomyopathy (one case) and acute myocardial infarction (one case). The subjects 
had a medical history including various risk factors. Patients who have risk factors associated with 
cardiac disease should be monitored and appropriate precautions taken. 
 



5 

Large cell transformation (LCT) 
There are limited data available on patients with LCT. 
 
Other 
Mogamulizumab should not be administered subcutaneously or intramuscularly, by rapid intravenous 
administration, or as an intravenous bolus. 
 
This medicinal product contains less than 1 mmol sodium per dose, that is to say essentially ‘sodium 
free’. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
No interaction studies have been performed. 
 
4.6 Fertility, pregnancy and lactation 
 
Women of childbearing potential/Contraception in males and females 
Women of childbearing potential and males of reproductive potential should use effective 
contraception during treatment with POTELIGEO and for at least 6 months after treatment.  
 
Pregnancy 
There are no data from the use of mogamulizumab in pregnant women. Although mogamulizumab 
crosses the placental barrier in cynomolgous monkey, apart from the pharmacological effect in 
foetuses, animal studies do not indicate direct or indirect harmful effects with respect to reproductive 
toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of 
mogamulizumab during pregnancy. 
 
Breast-feeding 
It is unknown whether mogamulizumab is excreted in human milk. Human IgGs are known to be 
excreted in breast milk during the first few days after birth, which is decreasing to low concentrations 
soon afterwards; consequently, a risk to the breast-fed child cannot be excluded during this short 
period. Afterwards POTELIGEO could be used during breast-feeding if clinically needed. 
 
Fertility 
There are no clinical data available on the effect of mogamulizumab on human fertility. No specific 
studies in animals have been performed to evaluate the effect of mogamulizumab on fertility. No 
adverse effects on male and female reproductive organs were observed in repeat-dose toxicity studies 
in cynomolgus monkeys (see section 5.3).  
 
4.7 Effects on ability to drive and use machines 
 
Mogamulizumab has minor influence on the ability to drive and use machines. Fatigue may occur 
following administration of mogamulizumab (see section 4.8). 
 
4.8 Undesirable effects 
 
Summary of the safety profile 
The most frequently reported serious adverse reactions were pneumonia, pyrexia, infusion related 
reaction and cellulitis.  
 
The most frequently reported adverse reactions were infusion-related reaction and rash (drug 
eruption); most of these reactions were non-serious and Grades 1 or 2.  
 
Severe adverse reactions included Grade 4 respiratory failure (1.1%) and Grade 5 reactions were 
polymyositis and sepsis (0.5% each). 
 



6 

Tabulated list of adverse reactions  
The adverse reactions are presented by system organ class and frequency categories, defined using the 
following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to 
<1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the 
available data). Within each frequency grouping, undesirable effects are presented in order of 
decreasing seriousness. 
 
Table 1: Adverse drug reactions occurring in patients receiving POTELIGEO (N=184) 
System organ class (SOC) Frequency Adverse reaction 

Blood and lymphatic system disorders Common Anaemia, neutropenia, leukopenia, Thrombocytopenia 
Endocrine disorders Common Hypothyroidism 

Gastrointestinal disorders Very common 
Constipation, diarrhoea, nausea, 
stomatitis 

Common Vomiting 
General disorders and administration site 
conditions Very common Fatigue, oedema peripheral, pyrexia 

Hepatobiliary disorders Uncommon Hepatitis acute, hepatitis 

Infections and infestations Very common Infections
a 

Common Upper respiratory tract infection 
Injury, poisoning and procedural 
complications Very common Infusion related reaction 

Investigations Common 

Alanine aminotransferase increased, 
aspartate aminotransferase increased, 
blood alkaline phosphatase increased, 
lymphocyte count decreased 

Metabolism and nutrition disorders Uncommon Tumour lysis syndrome 
Nervous system disorders Very common Headache 
Skin and subcutaneous tissue disorders Very common Drug eruption (including skin rash) 
a Folliculitis, Cellulitis, Candidiasis, Pneumonia, Sepsis, Skin infection, Otitis externa, Herpes zoster, 
Staphylococcal skin infection, Urinary tract infection, Herpes simplex and cytomegalovirus 
 
Description of selected adverse reactions 
 
Dermatologic reactions 
Patients receiving POTELIGEO have experienced drug rash (drug eruption), some of which were 
severe and/or serious. The majority of treatment-related dermatologic reactions were Grade 1 or 2, 
with Grade ≥3 drug rash occurring in 4.3% of patients. No trend in latency to event onset was 
identified for drug eruptions and rashes; both early and late-onset events occurred. 
 
Infusion-related reactions  
Infusion-related reactions have been observed in 33% of patients treated with POTELIGEO. The 
majority of treatment-related infusion-related reactions were Grade 1 or 2 and occurred during or 
shortly after the first infusion. Severe reactions (Grade 3) were experienced by 4% of patients.  
 
The incidence of infusion related reactions was highest after the first infusion (28.8% of subjects), 
reducing to ≤ 3.8% of subjects after two or more infusions.  
 
Infusion interruptions occurred in approximately 6% of patients, most of which (approximately 90%) 
occurred within the first cycle of treatment with mogamulizumab.  
 
Less than 1% of patients treated in Study 0761-010 discontinued treatment due to infusion-related 
reactions. 
 



7 

Serious infections 
Patients with MF or SS are at increased risk of serious infection due to the disruption of dermal 
integrity caused by cutaneous disease, as well as the immunosuppressive effects of extracutaneous 
disease, and treatment with mogamulizumab may increase that risk. Serious infections, including 
sepsis, pneumonia and skin infections, were experienced by 14.3% of subjects receiving 
mogamulizumab. The latency to event onset following the first dose varied considerably. The majority 
of patients recovered from infection. In the clinical trial (0761-010), there were 2 reports of respiratory 
failure with fatal outcome in patients with severe pneumonia occurring more than 9 months after 
starting treatment with mogamulizumab. 
 
Immunogenicity 
As with all therapeutic proteins, there is a potential for immunogenicity. A small percentage of 
patients receiving POTELIGEO tested positive for treatment emergent (treatment induced or treatment 
boosted) anti mogamulizumab antibodies. There were no positive neutralising antibody responses. 
 
Safety post last dose 
Of the 320 subjects exposed to mogamulizumab in Study 0761-010, 21 (6.6%), experienced at least 
one serious adverse drug reaction (SADR) that occurred within 90 days from the date of last study 
drug administration.  
 
Of these, SADRs that were reported in more than one patient were coded under the SOCs Infections 
and infestations (7 [2.2%] patients), General disorders and administration site conditions (5 [1.6%] 
patients), Respiratory, thoracic and mediastinal disorders (4 [1.3%] patients), Musculoskeletal and 
connective tissue disorders (3 [0.9%] patients), Hepatobiliary disorders (2 [0.6%] patients), and Injury, 
poisoning and procedural complications (2 [0.6%] patients). All remaining SOCs reported SADRs in 
one patient (0.3%). 
 
The safety profile observed in the 90 days following the last dose of mogamulizumab is consistent 
with the safety profile observed during the study treatment period. 
 
Elderly population 
The safety profile in elderly patients (≥ 65 years) was generally consistent with that of adult patients, 
except for dermatologic reactions and infusion related reactions which were seen more often in older 
subjects. 
 
Reporting suspected adverse reactions  
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V. 
 
4.9 Overdose 
 
There is no information on overdose with mogamulizumab. In case of overdose, the patient, including 
their vital signs, should be closely monitored (for at least 1 hour) and supportive treatment should be 
administered if required. 
 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1 Pharmacodynamic properties 
 
Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, monoclonal antibodies 
ATC code: L01XC25 
 



8 

Mechanism of action 
Mogamulizumab is a defucosylated, humanised IgG1 kappa immunoglobulin that selectively binds to 
CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of 
lymphocytes to various organs including the skin, resulting in depletion of the target cells. CCR4 is 
expressed on the surface of some cancer cells including T cell malignancies, such as MF and SS in 
which CCR4 expression is inherent. 
 
Clinical efficacy and safety 
The efficacy of mogamulizumab in the treatment of patients with mycosis fungoides (MF) or Sézary 
syndrome (SS) was established in a Phase 3, multicentre, open-label, study (0761-010) of 372 adult 
patients randomised 1:1 to treatment with either mogamulizumab or vorinostat. Each arm enrolled 
186 patients. Mogamulizumab infusion was administered at a dose of 1 mg/kg once weekly for the 
first 28-day cycle (on Days 1, 8, 15 and 22), and on days 1 and 15 of subsequent 28-day cycles. 
Vorinostat was administered at a starting dose of 400 mg orally, once daily beginning on day 1 for 28-
day cycles. Vorinostat patients with disease progression or unacceptable toxicities were permitted to 
cross over to mogamulizumab therapy. Crossover patients received up to 46 months of 
mogamulizumab therapy, as of December 2016 data cut. Treatment with mogamulizumab continued 
until disease progression or unacceptable toxicity. The trial excluded patients with active autoimmune 
diseases, central nervous system metastasis, and medical conditions that required systemic 
corticosteroids or other immunosuppressive medicinal products, or an active infection requiring 
therapy, including HIV, or hepatitis B or C. Patients with ECOG performance status ≥2 were also 
excluded. At study baseline, 38% had stage IB-II disease, 10% stage III, 52% stage IV. This study 
included patients regardless of their baseline level of CCR4 expression in skin biopsy. 
 
The primary efficacy endpoint was progression-free survival (PFS) based on investigator assessment 
using a global composite response criteria that took into account all potentially affected disease 
compartments (skin, blood, lymph nodes and viscera). Response in skin and blood was evaluated 
every 4 weeks. Response in lymph nodes and viscera was evaluated at 4 weeks, then every 8 weeks in 
the first year, and then every 16 weeks thereafter. 
 
All patients had a histologically confirmed diagnosis of mycosis fungoides (MF), 56.5%, 53.2%, or 
Sézary Syndrome (SS), 43.5%, 46.8%, in the mogamulizumab and vorinostat groups, respectively, and 
had received at least one prior systemic therapy. The most common prior systemic therapies used by 
subjects in Europe were bexarotene (70%), interferon (59%), methotrexate (49%), extracorporeal 
photopheresis (ECP) (31%) and gemcitabine/gemcitabine regimens (28%). 
 
The median duration of exposure with mogamulizumab was 5.6 months (range: <1 to 45.3 months). 
56% of patients received mogamulizumab for at least 6 cycles, and 25% of patients received 
mogamulizumab for at least 12 cycles. 
 
Patients were a median age of 64 years at the time of screening (range 25 to 101 years), 49.5% were 
65 years or older, and 58.1% were male. 
 
CCR4 expression was assessed retrospectively on pretreatment skin biopsies (formalin fixed paraffin 
embedded) using immunohistochemistry. In the mogamulizumab arm, baseline CCR4 expression 
levels were available in 75% of patients (N=140). CCR4 was detected on ≥1% of lymphocytes in 
100% of patients, and 96% (134/140) had CCR4 detected on ≥10% of skin lymphocytes.  
 
Of the patients randomised to vorinostat, 136 patients (73.1%) crossed over to mogamulizumab during 
the study. Reasons for crossover to mogamulizumab were disease progression (109 patients) and 
treatment intolerance (27 patients). The number of infusions of mogamulizumab administered to 
crossover patients ranged from 1 to 94 (up to 46 months of treatment) as of the December 2016 
datacut.  
 
At 6, 12, 18 and 24 months after the start of randomised treatment, the percent of subjects alive 
without disease progression was higher for mogamulizumab (55.3%, 38.3%, 28.0%, and 14.1%, 
respectively) compared to vorinostat (28.8%, 15.3%, 7.2%, and 7.2%, respectively). Median PFS for 



9 

the mogamulizumab group was 7.70 months (95% CI: 5.67, 10.33) and 3.10 months (95% CI: 2.87, 
4.07) for the vorinostat group with resultant hazard ration of 0.53 (95% CI: 0.41, 0.69), p<0.0001 (2-
sided, stratified log rank test).  
 
The Kaplan-Meier curve for PFS is shown Figure 1. 
 
Figure 1: Plot of Kaplan-Meier curve of progression-free survival by investigator’s assessment 
(ITT) population 

 
 
Key secondary endpoints were overall response rate (ORR), ORR after crossover, duration of response 
(DOR), and changes from baseline of the Skindex-29 Symptoms and Functional Scales, and 
Functional Assessment of Cancer Therapy-General (FACT-G) Physical and Functional Well-being 
domains. 
 
Overall response was reported as a composite score from measures in each compartment, and a 
response had to be demonstrated at two successive overall disease assessments (at least 8 weeks apart 
during the first year and 16 weeks apart thereafter) in order to be confirmed. Patients were included in 
the analysis for a specific compartment if they had presence of disease in that compartment at 
baseline, or had any post-baseline response assessment for that compartment. 
 
Table 2 summarises ORR and DOR, and response by compartment. The study demonstrated 
statistically significant improvements in ORR and response by compartment in the blood, skin, and 
lymph nodes as compared to vorinostat. Response in the viscera could not be evaluated due to limited 
efficacy data in subjects with visceral involvement; the benefit-risk of mogamulizumab in subjects 
with visceral involvement is currently undetermined due to lack of data. 
  



10 

Table 2: Response during randomised treatment period in study 0761-010 (intent-to-treat) 
 Mogamulizumab 

N=186  
Vorinostat 

N=186 
Overall response rate  
(confirmed CR + PR, %)  

28.0  4.8 

95% CI (21.6, 35.0)  (2.2, 9.0)  
P-valuea <.0001 

Duration of response (months)   
Median (95% CI) 14.1 (9.4, 19.2)  9.13 (4.7,-) 
Response by compartment   
Blood n=124  n=125 

Response rate (confirmed CR + PR, %) 66.9 18.4  
95% CI (57.9, 75.1)   (12.0, 26.3) 

P-valuea <0.0001 
Skin n=186  n=186 

Overall response rate (confirmed CR + PR, %) 41.9  15.6 
95% CI (34.8, 49.4)   (10.7, 21.6) 

P-valuea <.0001 
Lymph nodes n=136  n=133 

Overall response rate (confirmed CR + PR, %) 15.4  3.8 
95% CI (9.8, 22.6)   (1.2, 8.6) 

P-valuea 0.0008 
Viscera n=6 n=4 

Overall response rate (confirmed CR + PR, %) 0 0 
95% CI (0.0, 45.9)   (0.0, 60.2) 

Note: Overall response rate is based on Global Composite Response score. 
a: P-value was obtained from Cochran-Mantel-Haenszel test adjusting for disease type, disease stage, and region. 
CI=confidence interval; CR=complete response; PR=partial response 
 
Treatment with mogamulizumab resulted in 8 confirmed complete responses (complete clearing of all 
affected compartments) compared with 0 patients on vorinostat: 4 of these 8 patients were initially 
randomized to mogamulizumab and 4 had crossed over to mogamulizumab during the study. Forty-
one of the 136 cross-over patients (30.1%) responded with either partial or complete response with 
mogamulizumab. 
 
There are limited efficacy data in patients with low (<10%) CCR4 expression in the skin. In Study 
0761-010 there were 10/290 evaluable patients with CCR4 expression <10%, of which 6 were 
randomised to mogamulizumab, and 4 were randomised to vorinostat and subsequently crossed over to 
mogamulizumab. No confirmed responses were observed in these 10 subjects with low (<10%) CCR4 
expression. Compartmental responses were seen in 3 of 10 evaluable subjects treated with 
mogamulizumab in the randomised or cross over phase. 
 
Patients with stage IB/II disease treated with mogamulizumab had confirmed ORR of 17.6% 
compared to 8.3% for vorinostat, and compartment level (blood, skin, lymph node) response rates that 
were higher than those for vorinostat treated patients (Table 3). Overall, the median period of 
progression free survival for stage IB/II subjects treated with mogamulizumab was 4.7 months 
compared to 3.9 months for vorinostat-treated patients (Table 4).  In patients with stage IB/II disease, 
given the limited number of subjects with a response and immaturity of the data, no conclusion on 
duration of response can be made. 
 
Time to compartment level response in Stage IB/II patients was approximately 3 months, which is 
consistent with time to response for the ITT population overall (approximately 3 months). If a 
compartment level response or overall response is not observed after 3 months of treatment, 
discontinuation of treatment should be considered. 
 



11 

Table 3: Overall and Compartmental Response Rate in Early Disease Stages  
Mogamulizumab Vorinostat Risk Diff (M vs. V) 

Disease stage IB/II N=68 N=72  
Overall response rate (ORR), n (%) 12 (17.6) 6 (8.3) 9.3 
Compartment:    
Blood (n) 17 23  
 Response Rate (n, %) 8 (47.1) 4 (17.4) 29.7 
  95% CIa (23.0, 72.2) (5.0, 38.8) (-2.2, 57.1) 
Skin (n) 68 72  
 Response Rate (n, %) 19 (27.9) 14 (19.4) 8.5 
  95% CIa (17.7, 40.1) (11.1, 38.8) (-8.3, 24.9) 
Nodal (n) 41 40  
 Response Rate (n, %) 4 (9.8) 1 (2.5) 7.3 
  95% CIa (2.7, 23.1) (0.1, 13.2) (-14.3, 28.6) 

M=mogamulizumab. V= vorinostat 
 
Table 4: Progression Free Survival (PFS) by Treatment Group and Disease Stage (Randomised 
Treatment Period) 

 Mogamulizumab Vorinostat P value 
PFS, months 
ITT Population 7.70 (5.67, 10.33) 3.10 (2.87, 

4.07) 
<0.0001 

IB/II 4.7 (2.9 -7.47) 3.9 (2.87-
4.73) 

0.6790 

III/IV 10.9 (7.03-15.03) 3.0 (2.83-
3.87) 

<0.0001 

ITT=intent to treat 
 
Paediatric population 
The European Medicines Agency has waived the obligation to submit the results of studies with 
mogamulizumab in all subsets of the paediatric population in cutaneous T-cell lymphoma (CTCL) 
(MF and SS are subtypes of CTCL). See section 4.2 for information on paediatric use. 
 
5.2 Pharmacokinetic properties 
 
The pharmacokinetics (PK) of mogamulizumab was evaluated in adult patients with T-cell leukaemia-
lymphoma (ATL) and CTCL over a dose range of 0.01 to 1 mg/kg administered as multiple doses of 
mogamulizumab every week or every 2 weeks, and included the recommended 1.0 mg/kg dose and 
regimen (days 1, 8, 15 and 22 for the first 28-day cycle and on Days 1 and 15 for subsequent 28-day 
cycles). The population PK analysis included 444 patients receiving mogamulizumab in six clinical 
trials. The exposure to mogamulizumab increased proportionally with dose over the dose range of 0.1 
to 1.0 mg/kg. 
 
Absorption 
Mogamulizumab is dosed via intravenous route and therefore is immediately and completely 
bioavailable. 
 
Distribution 
Based on a population PK analysis, the geometric mean [% coefficient of variation (CV%)] central 
volume of distribution (Vc) was 3.57 L (20.1%). 
 
Biotransformation 
The metabolic pathway of mogamulizumab has not been characterised. Mogamulizumab is expected 
to be degraded into small peptides and amino acids via catabolic pathways in the same manner as 
endogenous IgG. 
 
Elimination 
Based on a population PK analysis, the geometric mean (% coefficient of variation [CV%]) clearance 
(CL) is 12.0 mL/h (83.7%) and geometric mean elimination half-life (t1/2) is 17 days (65.5%). 



12 

 
Linearity and accumulation 
Mogamulizumab exhibits linear PK from the dose in a dose range of 0.01 mg/kg to 1 mg/kg. Based on 
a population PK analysis, the steady-state concentrations of mogamulizumab were reached after 
12 weeks of repeated dosing when administered using the recommended regimen, and systemic 
accumulation was 1.7-fold. On a power model analysis, no deviation from dose proportionality was 
evident. 
 
Renal impairment 
The effect of renal impairment on the clearance of mogamulizumab was evaluated by a population PK 
analysis in patients with mild (creatinine clearance [CrCL] between 60 and 89; n= 157), moderate 
(CrCL between 59 and 30; n= 80), or severe renal impairment (CrCL less than 30 mL/min; n= 2). No 
clinically important differences in the clearance of mogamulizumab were found between patients with 
mild to severe renal impairment and patients with normal renal function. 
 
Hepatic impairment 
The effect of hepatic impairment on the clearance of mogamulizumab was evaluated by a population 
PK analysis in patients with mild hepatic impairment (total bilirubin [TB] less than or equal to the 
upper limit of normal [ULN] and AST greater than ULN or TB less than 1 to 1.5 times ULN and any 
AST; n= 80) or moderate (TB greater than 1.5 to 3 times ULN and any AST; n=3) hepatic impairment. 
No clinically important differences in the clearance of mogamulizumab were found between patients 
with mild to moderate hepatic impairment and patients with normal hepatic function. Mogamulizumab 
has not been studied in patients with severe hepatic impairment (TB greater than 3 times ULN and any 
AST). 
 
Other special populations 
The effects of various covariates on the PK s of mogamulizumab were assessed in population PK 
analyses. The following factors had no clinically important effect on the CL of mogamulizumab: age 
(range: 22 to 101 years), sex, ethnicity (other than Japanese, limited data are available in other ethnic 
populations), renal impairment, mild or moderate hepatic impairment, disease subtype (mycosis 
fungoides (MF) or Sézary Syndrome (SS)), degree of CCR4 expression or ECOG status, although it 
should be noted that patients with ECOG PS ≥2 were excluded from the clinical trials. 
 
Pharmacokinetic/pharmacodynamic relationship(s) 
Efficacy 
Exposure-Response analysis indicated that efficacy was not correlated with mogamulizumab exposure 
in the pivotal study. Efficacy, as measured by improvement in PFS based on investigator assessment, 
was not associated with increasing mogamulizumab exposure.   
 
5.3 Preclinical safety data 
 
Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose 
toxicity. Carcinogenicity or genotoxicity studies have not been conducted with mogamulizumab. No 
specific studies have been conducted to evaluate potential effects on fertility. 
 
No mogamulizumab-related toxic effects in the male and female reproductive organs were observed in 
repeat-dose toxicology studies in sexually mature monkeys up to 26 weeks. 
 
In an animal reproductive and developmental toxicity study, administration of mogamulizumab to 
pregnant cynomolgus monkeys from the start of organogenesis through delivery did not show a 
potential for embryo-foetal lethality, teratogenicity, or foetal growth retardation. In general, IgG 
molecules are known to cross the placental barrier and mogamulizumab concentrations in foetus 
plasma were detected.  Pharmacological activity of mogamulizumab was noted in foetuses as was 
evident from a decrease in CCR4 expressing lymphocytes. 
 
 



13 

6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
 
Citric acid monohydrate 
Glycine  
Polysorbate 80  
Sodium hydroxide (for pH adjustment) 
Hydrochloric acid (for pH adjustment) 
Water for injections  
 
6.2 Incompatibilities 
 
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 
products. Mogamulizumab should not be infused concomitantly in the same intravenous line with 
other medicinal products. 
 
6.3 Shelf life 
 
Unopened vial 
3 years 
 
After opening 
POTELIGEO does not contain a preservative. Once opened, the medicinal product should be diluted 
and infused immediately (see section 6.6).  
 
After preparation of infusion 
Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature (at 
25°C) under ambient room light.  
These time limits include storage of the infusion solution in the infusion bag through the duration of 
infusion. From a microbiological point of view, the product must be used immediately.  
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the 
user and must not be longer than a total of 4 hours at 2°C - 8°C provided that dilution has taken place 
under controlled and validated aseptic conditions. 
 
6.4 Special precautions for storage 
 
Store in a refrigerator (2ºC to 8ºC).  
Do not freeze. 
Keep the vial in the outer carton in order to protect from light. 
For storage conditions after dilution of the medicinal product, see section 6.3  
 
6.5 Nature and contents of container 
 
5 mL solution in a 10 mL glass vial (type I glass) with a rubber stopper, an aluminium seal and a 
polypropylene flip-off cap.  
 
Pack of 1 vial. 
 



14 

6.6 Special precautions for disposal and other handling 
 
Preparation 
• Visually inspect the medicinal product for particulate matter and discolouration prior to 

administration. POTELIGEO is a clear to slightly opalescent, colourless solution. Discard the 
vial if cloudiness, discolouration or particulates are observed. 

• Calculate the required volume of POTELIGEO needed to prepare the infusion solution for the 
1 mg/kg dosage based on patient weight (see section 4.2). Aseptically withdraw the required 
volume of POTELIGEO into the syringe and transfer into an infusion bag containing 9mg per 
ml (0.9%) sodium chloride solution for injection. Mix diluted solution by gentle inversion. Do 
not shake. The final concentration of the diluted solution should be between 0.1 mg/mL to 
3.0 mg/mL. 

• Each vial is for single use only. Discard any unused portion left in the vial in accordance with 
local requirements. 

 
Administration 
• The diluted solution is compatible with polyvinyl chloride (PVC) or polyolefin (PO) infusion 

bags. 
• Do not mix POTELIGEO with, or administer as an infusion with, other medicinal products.  
• POTELIGEO is intended for intravenous use only, and should not be administered 

subcutaneously, intramuscularly, as a bolus dose or by rapid intravenous administration. 
• Administer infusion solution over at least 60 minutes through an intravenous line containing a 

sterile, low protein binding 0.22 micron (or equivalent) in-line filter. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132NP Hoofddorp 
Netherlands  
 
 
8. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/18/1335/001 
 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
Date of first authorisation: 22 November 2018 
 
 
10. DATE OF REVISION OF THE TEXT 
 
Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu 
 
  



15 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX II 
 

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE 
SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR 
BATCH RELEASE  

 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND 

USE 
 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 
 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE 

SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
 
  



16 

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND 
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 

 
Name and address of the manufacturer(s) of the biological active substance(s) 
 
Kyowa Kirin Co., Ltd. 
Takasaki Plant 
100-1 Hagiwara-machi, Takasaki-shi, 
Gunma, 370-0013, Japan 
 
Name and address of the manufacturer(s) responsible for batch release 
 
Piramal Healthcare UK Limited 
Whalton Road 
Northumberland 
Morpeth 
NE61 3YA 
United Kingdom 
 
allphamed PHARBIL Arzneimittel GmbH 
Hildebrandstr. 10-12 
37081 Göttingen 
Germany 
 
The printed package leaflet of the medicinal product must state the name and address of the 
manufacturer responsible for the release of the concerned batch. 
 
 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
 
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 
Characteristics, section 4.2). 
 
 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 
 
• Periodic safety update reports 
 
The requirements for submission of periodic safety update reports for this medicinal product are set 
out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 
2001/83/EC and any subsequent updates published on the European medicines web-portal. 
The marketing authorisation holder shall submit the first periodic safety update report for this product 
within 6 months following authorisation. 
 
 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 
 
• Risk Management Plan (RMP) 
 
The MAH shall perform the required  pharmacovigilance activities and interventions detailed in the 
agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreeed  subsequent 
updates of the RMP. 
 
An updated RMP should be submitted: 
 



17 

• At the request of the European Medicines Agency; 
 
• Whenever the risk management system is modified, especially as the result of new information 
being received that may lead to a significant change to the benefit/risk profile or as the result of an 
important (pharmacovigilance or risk minimisation) milestone being reached. 
 
  



18 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX III 
 

LABELLING AND PACKAGE LEAFLET 
  



19 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

A. LABELLING 



20 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
 
OUTER CARTON 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
POTELIGEO 4 mg/mL concentrate for solution for infusion 
mogamulizumab 
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
Each mL of concentrate contains 4 mg of mogamulizumab. 
Each vial of 5 mL contains 20 mg of mogamulizumab. 
 
 
3. LIST OF EXCIPIENTS 
 
Citric acid monohydrate, glycine, polysorbate 80, sodium hydroxide, hydrochloric acid, water for 
injections. See leaflet for further information.  
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Concentrate for solution for infusion 
20 mg/5 mL 
1 vial 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Read the package leaflet before use. 
Intravenous use after dilution. 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children. 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
For single use only. 
Do not shake. 
 
 
8. EXPIRY DATE 
 
EXP 
 
 



21 

9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator (2ºC to 8ºC).  
Do not freeze.  
Store in the original carton in order to protect from light. 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132NP Hoofddorp 
Netherlands 
 
 
12. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/18/1335/001 
 
 
13. BATCH NUMBER 
 
Lot 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 
 
 
17. UNIQUE IDENTIFIER – 2D BARCODE 
 
2D barcode carrying the unique identifier included. 
 
 
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 
 
PC:  
SN:  
NN:  



22 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
 
VIAL LABEL 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
POTELIGEO 4 mg/mL concentrate for solution for infusion 
mogamulizumab 
Intravenous use after dilution 
 
 
2. METHOD OF ADMINISTRATION 
 
Read the package leaflet before use. 
 
 
3. EXPIRY DATE 
 
EXP 
 
 
4. BATCH NUMBER 
 
Lot 
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
20 mg/5 mL 
 
 
6. OTHER 
 
For single use only. 
  



23 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

B. PACKAGE LEAFLET 



24 

Package leaflet: Information for the patient 
 

POTELIGEO 4 mg/mL concentrate for solution for infusion 
mogamulizumab 

 
This medicine is subject to additional monitoring. This will allow quick identification of new 

safety information. You can help by reporting any side effects you may get. See the end of section 4 
for how to report side effects. 
 
Read all of this leaflet carefully before you start using this medicine because it contains 
important information for you. 
- Keep this leaflet. You may need to read it again.  
- If you have any further questions, ask your doctor or nurse. 
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects 

not listed in this leaflet. See section 4. 
 
What is in this leaflet 
1. What POTELIGEO is and what it is used for  
2. What you need to know before you use POTELIGEO 
3. How POTELIGEO is given 
4. Possible side effects  
5. How to store POTELIGEO  
6. Contents of the pack and other information 
 
 
1. What POTELIGEO is and what it is used for 
 
POTELIGEO contains the active substance mogamulizumab, which belongs to a group of medicines 
called monoclonal antibodies. Mogamulizumab targets cancer cells which are then destroyed by the 
immune system (the body’s defence). 
 
This medicine is used to treat adults with mycosis fungoides and Sézary syndrome, which are types of 
cancers called cutaneous T-cell lymphomas.  The medicine is for use in patients who have received at 
least one medicine given by mouth or by injection. 
 
 
2. What you need to know before you use POTELIGEO 
 
Do not use POTELIGEO if you are: 
- allergic to mogamulizumab or any of the other ingredients of this medicine (listed in section 6). 
 
Warnings and precautions 
Talk to your doctor or nurse before using POTELIGEO if you: 
- ever had a severe skin reaction with this medicine. 
- ever had an infusion reaction with this medicine (possible symptoms of an infusion reaction are 

listed in section 4). 
- have human immunodeficiency virus (HIV), herpes, cytomegalovirus (CMV), or hepatitis B or 

C infection, or other on-going infections.  
- have had or plan to have a stem cell transplant, either using your own cells or a donor’s.  
- have had tumour lysis syndrome (a complication involving the destruction of cancer cells) after 

a previous treatment. 
- have heart problems. 
 
Tell the person giving you the infusion or get medical help straight away if you experience a 
reaction during or after any POTELIGEO infusion. 
 



25 

Tell your doctor immediately if you experience any of the serious side effects listed in Section 4 
after starting POTELIGEO treatment. 
 
Children and adolescents 
This medicine should not be used in children and adolescents below 18 years of age. 
 
Pregnancy and breast-feeding 
The effects of POTELIGEO in pregnancy and breast-feeding are not known. Due to the mechanism of 
action of the medicine, it may harm your baby if it is administered when you are pregnant or 
breast- feeding. 
 
If you can get pregnant, you will need to use effective contraception during and for at least six months 
after receiving this treatment. If you are breast-feeding, you should discuss with your doctor whether 
you can breast-feed during or after treatment with POTELIGEO. 
 
You must tell your doctor or nurse if you are pregnant, breast-feeding, think you may be pregnant, or 
are planning to have a baby.  
 
Men 
You will need to use effective contraception during and for at least six months after receiving this 
treatment.  
 
Driving and using machines 
POTELIGEO is unlikely to affect your ability to drive and use machines. However, the medicine can 
cause tiredness in some people, so take particular care when driving and using machines until you are 
certain that this medicine does not affect you.  
 
POTELIGEO contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially 
‘sodium-free’. 
 
 
3. How POTELIGEO is given 
 
The amount of POTELIGEO you will receive is calculated by your doctor based on your body weight.  
The recommended dose is 1mg POTELIGEO for each kg of body weight. 
 
POTELIGEO will be given to you through a vein (intravenous infusion) over at least 60 minutes. To 
start with, the infusions will be given once a week for the first 5 doses, then once every 2 weeks. 
Treatment should be continued unless you get serious side effects or the cutaneous T-cell lymphoma 
starts to get worse.  
 
 



26 

4. Possible side effects 
 
Like all medicines, this medicine can cause side effects, although not everybody gets them. 
 
Serious side effects 
 
Tell your doctor or nurse or get medical help immediately if you have any of the following 
symptoms after starting POTELIGEO:  
- chills, nausea or vomiting, headache, wheezing, itching, flushing, rash, dizziness or feeling 

faint, difficulty breathing and fever, which may be signs of an infusion reaction. If this happens, 
the infusion may need to be stopped and you may require additional treatment. When the 
symptoms go away, POTELIGEO can normally continue to be given, but more slowly. Your 
doctor may stop POTELIGEO treatment if your reaction is severe.  

- signs of infection, which may include a fever, sweats or chills, flu-like symptoms, sore throat or 
difficulty swallowing, cough, shortness of breath, stomach pain, nausea or vomiting, diarrhoea 
and feeling very unwell.  

- skin pain, itching, skin blisters, skin rash or sore mouth, which are possible signs that you may 
be developing a severe skin reaction, such as Stevens-Johnson syndrome or toxic epidermal 
necrolysis.  

- chest pain, shortness of breath, fast or slow heartbeat, sweating, dizziness, nausea or vomiting, 
weakness, feeling faint and feeling unwell. Although unlikely to be caused by this medicine, 
these may be signs of a heart disorder. 

- fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark 
or cloudy urine, unusual tiredness and/or muscle or joint pain. The destruction of cancer cells 
and the body’s reaction to it can very occasionally lead to a problem called tumour lysis 
syndrome. 

- if you go on to have a stem cell transplant, it is possible that you could then develop 
complications (graft versus host disease) that are difficult to manage. Symptoms may include 
skin rashes or blistering, nausea or diarrhoea that doesn’t go away, stomach pain or vomiting, 
joint pain or stiffness, dry or irritated eyes or blurred vision, mouth sores, irritation or pain, a 
cough that does not go away or difficulty breathing, sensitive genitals, jaundice (turning 
yellow), dark urine, and any swelling.  

 
Other side effects 
 
Talk to your doctor if you get any other side effects. These can include: 
 
Very common side effects (may affect more than 1 in 10 people):  
- Lack of energy (fatigue) 
- Constipation 
- Swollen legs or ankles  
- Headache 
 
Common side effects (may affect up to 1 in 10 people): 
- Anaemia (reduced red blood cells) 
- Reduced blood platelets (thrombocytopenia) 
- Reduced white blood cells (neutropenia and leucopenia) or reduced lymphocytes 
- Blood tests showing raised liver enzyme levels 
- Underactive thyroid 
 
Uncommon side effects (may affect up to 1 in 100 people) 
- Inflammation of the liver (hepatitis) 
 
Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 



27 

Appendix V. By reporting side effects, you can help provide more information on the safety of this 
medicine. 
 
 
5. How to store POTELIGEO 
 
Keep this medicine out of the sight and reach of children. 
 
Do not use this medicine after the expiry date which is stated on the carton and the vial after “EXP”. 
The expiry date refers to the last day of that month. 
 
Unopened vial: Store in a refrigerator (2ºC - 8ºC). Do not freeze. 
 
Store it in the original carton in order to protect from light 
 
Reconstituted/diluted solution: Use immediately or store in a refrigerator (2ºC - 8ºC) and use within 
4 hours. 
 
Do not use this medicine if you notice signs of deterioration, such as particulate matter or 
discolouration.  
 
Do not throw away any medicines via wastewater or household waste. These measures will help 
protect the environment. 
 
 
6. Contents of the pack and other information 
 
What POTELIGEO contains 
- Each vial contains 20 mg of mogamulizumab in 5 mL of concentrate, corresponding to 

4 mg/mL. 
- The other excipients are citric acid monohydrate, glycine, polysorbate 80, sodium hydroxide, 

hydrochloric acid, and water for injections. See section 2 “POTELIGEO contains sodium”. 
 
What POTELIGEO looks like and contents of the pack 
POTELIGEO is a clear, colourless solution. The pack contains a glass vial containing 5 mL 
concentrate for solution for infusion.  
 
Marketing Authorisation Holder 
Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132NP Hoofddorp 
Netherlands  
 
Manufacturer  
Piramal Healthcare UK Limited 
Whalton Road 
Morpeth 
NE61 3YA 
United Kingdom 
 
allphamed PHARBIL Arzneimittel GmbH 
Hildebrandstr. 10-12 
37081 Göttingen 
Germany 
 
 
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>. 



28 

 
Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments. 
 


	ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET